Share
Keith Carlton
Newronika, a pioneer in adaptive deep brain stimulation (AlphaDBS™) technology, has appointed Keith Carlton as its new Executive Chairman.
This appointment marks a significant step in reinforcing the company’s strategic leadership as it accelerates its global growth and commercialization efforts.
Mr. Carlton brings a wealth of experience in the medical device and neuromodulation industries, where he has consistently driven innovation, operational excellence, and strategic expansion. His leadership background includes guiding organizations through complex regulatory environments, building global partnerships, and scaling transformative technologies in highly competitive markets.
His appointment comes at a pivotal time for Newronika, as the company continues to advance its mission of revolutionizing neuromodulation therapy with its breakthrough AlphaDBS™ system - the first adaptive deep brain stimulation technology capable of recording brain signals and tailoring therapy in real-time.
The company recently achieved several major milestones, including CE Mark approval for AlphaDBS™, U.S. FDA Investigational Device Exemption (IDE) clearance, and the successful closing of a €13.6 million Series B funding round. These accomplishments have positioned Newronika as a front-runner in next-generation neuromodulation solutions.
With Carlton’s appointment, Newronika reinforces its commitment to advancing innovative therapies that redefine the standard of care in neurology worldwide.
